BANK VONTOBEL/CALL/ELI LILLY & CO/820/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 14:03:22 2024-06-14 EDT | ||
| 8.8 EUR | +0.34% |
|
| Current month | +64.18% | ||
| 1 month | +177.60% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 8.8 | +0.34% |
| 24-06-13 | 8.77 | +13.02% |
| 24-06-12 | 7.76 | -1.02% |
| 24-06-11 | 7.84 | +1.03% |
| 24-06-10 | 7.76 | +6.01% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 02:03 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VM9ZDV |
| ISIN | DE000VM9ZDV6 |
| Date issued | 2024-02-07 |
| Strike | 820 $ |
| Maturity | 2024-09-20 (96 Days) |
| Parity | 10 : 1 |
| Emission price | 2.79 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.6 € |
|---|---|
| Lowest since issue | 2.47 € |
| Spread | 0.02 € |
| Spread % | 0.23% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
878.4
USD
Average target price
855.4
USD
Spread / Average Target
-2.63%
- Stock Market
- Warrants
- Warrant
